MARC details
| 000 -LEADER |
|---|
| fixed length control field |
02882cam a2200445 i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
23668002 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20260101144715.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr ||||||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
240130s2025 flu ob 001 0 eng |
| 010 ## - LIBRARY OF CONGRESS CONTROL NUMBER |
|---|
| LC control number |
2024003718 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| Canceled/invalid ISBN |
9781032517018 (hbk.) |
| 035 ## - SYSTEM CONTROL NUMBER |
|---|
| System control number |
(DLC)23668002 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
DLC |
| Language of cataloging |
eng |
| Description conventions |
rda |
| Transcribing agency |
JKRC |
| Modifying agency |
DLC |
| -- |
DLC-MRC |
| 060 00 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER |
|---|
| Classification number |
QV 241 |
| 082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
615.19 |
| Edition number |
23 |
| Item number |
NIA.S |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Niazi, Sarfaraz K. |
| Relator term |
author. |
| 9 (RLIN) |
38250 |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Biosimilars development strategies : |
| Remainder of title |
fast to market approaches / |
| Statement of responsibility, etc. |
by Sarfaraz K. Niazi. |
| Medium |
English. |
| 250 ## - EDITION STATEMENT |
|---|
| Edition statement |
1st. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Place of publication, distribution, etc. |
Boca Raton : |
| Name of publisher, distributor, etc. |
CRC Press Taylor & Francis Group, |
| Date of publication, distribution, etc. |
2025. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
viii, 187 p. ; |
| Dimensions |
24 cm. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Content type code |
txt |
| Source |
rdacontent |
| Authority record control number or standard number |
http://id.loc.gov/vocabulary/contentTypes/txt |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
computer |
| Media type code |
c |
| Source |
rdamedia |
| Authority record control number or standard number |
http://id.loc.gov/vocabulary/mediaTypes/c |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
online resource |
| Carrier type code |
cr |
| Source |
rdacarrier |
| Authority record control number or standard number |
http://id.loc.gov/vocabulary/carriers/cr |
| 365 ## - TRADE PRICE |
|---|
| Price amount |
120.00 |
| Currency code |
Pound |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Includes bibliographical references and index. |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
All About Biosimilars -- Product Type and Selection Strategies -- Development Master Plan -- Optimization of Cost of Goods -- Strategic Understanding for Biosimilars Future -- Repurposing Biosimilars. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
"After 18 years since the first biosimilar was approved, a lot has changed, from the regulatory guidelines to the stakeholder perceptions about the safety and efficacy of biosimilars. However, the development costs remain high, preventing faster entry into markets with more than 200 choices. Analyzing the regulatory filings of all approved biosimilars in the US and EU, a deep analysis of the scientific principles, and continuous challenges to the regulatory authorities have made it possible to plan the development on a fast track. This book teaches how to cut the current time and cost by more than 70%, based on the author's hands-on experience"-- Provided by publisher. |
| 588 ## - SOURCE OF DESCRIPTION NOTE |
|---|
| Source of description note |
Description based on print version record and CIP data provided by publisher. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Biosimilar Pharmaceuticals |
| 9 (RLIN) |
38251 |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Drug Development |
| 9 (RLIN) |
34167 |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Drug Design |
| 9 (RLIN) |
38252 |
| 758 ## - RESOURCE IDENTIFIER |
|---|
| Real World Object URI |
http://id.loc.gov/resources/instances/23668002 |
| 758 ## - RESOURCE IDENTIFIER |
|---|
| Relationship |
http://id.loc.gov/ontologies/bibframe/instanceOf |
| Real World Object URI |
http://id.loc.gov/resources/works/23668002 |
| 776 1# - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Relationship information |
Print version |
| Relationship |
http://id.loc.gov/entities/relationships/printversion |
| Main entry heading |
Niazi, Sarfaraz, 1949- |
| Title |
Biosimilars development strategies |
| Edition |
First edition |
| Place, publisher, and date of publication |
Boca Raton: CRC Press, 2025 |
| Record control number |
(DLC) 2024003717 |
| International Standard Book Number |
9781032517018 |
| -- |
9781032519586 |
| -- |
9781003404637 |
| 884 ## - DESCRIPTION CONVERSION INFORMATION |
|---|
| Conversion process |
DLC bibframe2marc v2.10-dev |
| Conversion date |
20250606 |
| Conversion agency |
DLC |
| Uniform Resource Identifier |
https://github.com/lcnetdev/bibframe2marc/releases/tag/v2.10-dev |
| 906 ## - LOCAL DATA ELEMENT F, LDF (RLIN) |
|---|
| a |
7 |
| b |
cbc |
| c |
orignew |
| d |
1 |
| e |
ecip |
| f |
20 |
| g |
y-gencatlg |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
|
| Koha item type |
Books |
| Edition |
23 |
| Suppress in OPAC |
No |